Acute Heart Failure, Cardiomyopathies, Dilated Cardiomyopathy, Ischemic Cardiomyopathy, Myocardial Infarction, Acute, NSTEMI - Non-ST Segment Elevation MI, Sepsis, STEMI - ST Elevation Myocardial Infarction
Conditions
Brief summary
MEtabolomics and MicrObiomics in caRdIovAscular diseases Mannheim (MEMORIAM) is a single-center, prospective and observational study investigating to identify disease-specific metabolic, respectively microbiomic, patterns of patients with high-risk cardiovascular diseases. High-risk cardiovascular diseases comprise patients suffering from acute heart failure (AHF), ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), sepsis, septic shock, ischemic and non-ischemic cardiomyopathy.
Detailed description
Scientific evidence about the metabolomic and microbiomic changes in high-risk cardiovascular patients is still lacking. The acute, critical or progressive disease status predestinies to relevant changes in cardiovascular metobolism. High-risk patients in the present trial comprise those with acute heart failure, myocardial infarction (STEMI and NSTEMI), sepsis, septic shock, ischemic and non-ischemic cardiomyopathy with severely reduced left ventricular ejection fraction (LVEF \<35%). Therfore this study investigates to identify disease-specific patterns of metabolic and microbiomic changes. These patterns may help to understand pathophysiology at the metabolic stages and find out those patients being at highest risk of adverse future outcome.
Interventions
OTHERBlood draw
venous blood withdraw (ca. 40ml)
Sponsors
Universitätsmedizin Mannheim
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
Yes
Inclusion criteria
* above mentioned diseases, diagnosis according to respective guideline * written informed consent
Exclusion criteria
* under 18 years * cancer * rheumatic diseases * infections (except septic group) * higher grade heart valve diseases
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disease-specific metabolic/microbiomic biomarker patterns. | Within 24h after disease onset | Expression of disease-specific metabolic/microbiomic biomarker patterns at the time of acute disease presentation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| All-cause and cardiovascular mortality. | 12 months after inclusion | All-cause and cardiovascular mortality, at 6 months and 12 months |
| Cardiac rehospitalization. | 12 months after inclusion | Cardiac rehospitalization, at 6 months and 12 months. |
Countries
Germany
Contacts
Primary ContactMichael Behnes, PD Dr.
Backup ContactIbrahim Akin, Prof. Dr.
Outcome results
None listed